Why Zimmer Biomet Holdings (ZBH) is on investors’ radar today

Zimmer Biomet Holdings (ZBH) has drawn attention after recent trading, with the stock closing at US$87.33 and showing mixed return patterns over the past year that contrast short term gains with longer term declines.

Recent trading highlights this contrast clearly, with a 7 day share price return of 6.07% and a 30 day gain of 5.43%, set against a 1 year total shareholder return that is down 4.48% and a 5 year total shareholder return that is down 40.68%. This suggests that recent momentum is building from a weaker long term base.

If Zimmer Biomet’s recent move has you thinking more broadly about healthcare technology, this could be a good moment to scan other specialists powered by artificial intelligence through our 39 healthcare AI stocks

With Zimmer Biomet trading at US$87.33 alongside an indicated intrinsic discount and a gap to analyst targets, the key question is whether this represents undervaluation or a stock that already reflects expectations for future growth.

Most Popular Narrative: 11.4% Undervalued

Zimmer Biomet’s most followed narrative pegs fair value at $98.52, above the last close at $87.33. This puts the focus firmly on earnings power and margins.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Want to see what sits behind that margin story and fair value gap? The narrative leans heavily on steadier revenue growth, rising profitability, and a lower future earnings multiple than many peers. The exact mix of those levers is what drives the $98.52 figure.

Result: Fair Value of $98.52 (UNDERVALUED)

However, this hinges on execution, with pricing pressure and tougher competition in orthopedic robotics both capable of quickly challenging the current undervaluation story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment mixed between opportunity and concern, this is a moment to move quickly, review the evidence, and weigh the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Zimmer Biomet has your attention, do not stop there. Use the Simply Wall Street Screener to quickly spot other opportunities that might fit your style.

• Target reliable cash generators by scanning companies with sturdy finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Hunt for mispriced opportunities by reviewing 49 high quality undervalued stocks that match strong fundamentals with appealing valuations.
• Get ahead of the crowd by tracking a screener containing 22 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.